 Greenwich LifeSciences, Inc. NASDAQ: GLSI is a biopharmaceutical company that is developing GP2, an immunotherapy to prevent breast cancer recurrences in certain patients. The stock skyrocketed nearly 3,000 in a single day in December after a Phase 2b trial suggested the therapy can reduce breast cancer recurrence rates down to zero. 